

Faculty of Medicine



0.0.0

The Power of Data Science in Drug Development

Continuing Education Series: Frontiers in Drug Development

Online Seminar Thursday, June 24, 2021 08:30 am – 4:30 pm

an Center of Pharmaceutical Medie



Under the auspices of EUCOR, the European Campus IFAPP, Int. Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine

Accredited by SwAPP/SGPM Recognized as PharmaTrain Centre of Excellence











Invitation

Data are the new currency in drug development: Artificial Intelligence (AI), Machine Learning and Deep Learning offer exciting opportunities to integrate and analyze the massive amount of data collected in clinical trials as well as in real-life healthcare settings and medical records.

Pharmaceutical industry and the Life Sciences have made great progress utilizing bioinformatics and data science, especially in drug discovery and clinical development, for example in image analysis, large scale genomic analysis, phenotypic profiling and analysis of high dimensional time-series data. More recently, AI and Machine Learning are being used in pharmacovigilance for the detection of Adverse Events from social media channels. Another recent use of data analytics on past and present operational data enables insights-driven decision making, increased productivity and transparency across a global drug development organization.

Real-world data (RWD) and real-world evidence (RWE) are playing an increasing role in health care decisions, for patient access and for policy making. More treatments come to market via expedited regulatory approvals with limited evidence from traditional clinical development programs. Regulatory authorities have a keen interest to accept RWE for marketing authorization, however, the conditions are still a matter of debate.

In this online seminar data science is being approached across the lifecycle, from data generation and data analysis, to data application and decision making, access and policy making. It brings together thought leaders and well-renowned experts from industry, regulatory agencies, health services and patient organizations who will discuss their perspectives and outlook on this rapidly evolving topic.

Join us on June 24, 2021 to learn from and discuss with the experts!



Prof. Dr. Thomas D. Szucs Director



Dr. Annette Mollet Head of Education & Training

8. Zonlinel

Dr. Stefanie Zechner Program Director

The Power of Data Science in Drug Development

Online, June 24, 2021	
	Chairperson: Karen M. Facey, Edinburgh
08:00	Opening of Zoom Meeting by ECPM as Host
	Data Science – A New Discipline in Drug R&D, from Bioinformatics to Medicine Bryn Roberts, F. Hoffmann-La Roche Ltd, Basel
	Data Science and AI in Pharma R&D and Beyond Luca Finelli, Novartis Pharma AG, Basel
10:00 - 10:30	Coffee Break
	Big Data 2021 – Big Data Landscape from a Regulatory Perspective n.n.
	Acceptance of Real World Data versus Randomized Controlled Trials for Marketing Authorization Lorenzo Hess, Swissmedic, Berne
12:00 - 13:00	Lunch Break
	Data Analytics in Pharmacovigilance Bertrand Limoges, Novartis Pharma AG, Basel How Real-World Evidence can Support Value Propositions and Access Karen M. Facey, Evidence Based Health Consultant, Edinburgh
14:30 - 15:00	Coffee Break
	Using Real World Evidence for Policy Making Mimi Choon-Quinones, International Myeloma Founda- tion & Partners for Patients, Basel
	How do Payers Utilise Data? Health Services Research Based on Claims Data Andri Signorell, Helsana, Zurich

About Frontiers in Drug Development Seminars

	ECPM offers one day seminars on new trends and develop- ments in drug development science. These seminars pro- vide the opportunity to integrate work and further educa- tion, to discuss with experts face-to-face and to build an international network. They take place on the fourth day of each of the six modules of the ECPM Diploma Course and are mandatory for students taking the Diploma Course. Ad- ditionally they are open to our alumni and other interested scientists and can be booked separately.
Learning Outcomes	
	 Participants should learn more about various topic such as: Future trends in drug development including Future Information Technologies, Nano-Technologies, Computer Simulation and Modeling, Personalized Medicine, Genomics, Biologicals and Biosimilars, Advanced Therapeutics. Regulatory Agency updates from FDA, EMA and Swissmedic. Ethical, Economic and Epidemiological Considerations and Concepts in Drug Development.
Date and Venue	
	Thursday, June 24, 2021
	This seminar will be held online via https://zoom.us/. All details will be shared in June 2021.
Registration	
	Via our homepage www.ecpm.ch or www.ecpm.ch/frontiers-in-drug-development-s6

Deadline for Registration: June 14, 2021

Six workshops over a period of two years, which equal 1 ECTS credit. Accredited as continuing education with eight credits by the Swiss Society of Pharmaceutical Medicine (SGPM) and the Swiss Society of Pharmaceutical Professionals (SwAPP).

Fee	
	Course fee including certificate and electronic course mate- rial is CHF 280 and CHF 230 for ECPM Alumni and SwAPP/ SGPM members. A reduced fee applies to participants from academia and nonprofit organizations.
	After registration you will receive an invoice. For short no- tice registration, please send a copy of the money transfer to ecpm@unibas.ch
Cancellation Policy	
	Refund of fees, less 30 % administrative charges will be given if cancellations are received in written format (ecpm@unibas.ch) by June 16, 2021. After this date no refund can be given for cancellations. Speakers are subject to change with- out notice.
Seminar Organizer	
	This seminar is organized by the European Center of Phar- ma–ceutical Medicine.

Educating Talents since 1460.

University of Basel ECPM Institute of Pharmaceutical Medicine Klingelbergstrasse 61 4056 Basel Switzerland

www.ecpm.ch

